Tau­Rx takes a slice of pos­i­tive da­ta and claims suc­cess af­ter a failed PhI­II Alzheimer’s study

Tau­Rx raised more than $225 mil­lion from some un­con­ven­tion­al fi­nanc­ing sources to back their big pair of Phase III stud­ies for a new drug to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.